Cancer antigen 125 levels and increased risk of new-onset atrial fibrillation

Yücel, Hasan; Kaya, Hakan; Zorlu, Ali; Yıldırımlı, Kutay; Sancakdar, Enver; Güneş, Hakan; Kurt, Recep; Ozgul, Ufuk; Turgut, Okan Onur; Yilmaz, Mehmet Birhan

doi:10.1007/s00059-014-4148-4

Cited by 18 publications

(14 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The increased CA-125 levels have been reported in different cardiac pathologies including CHF, coronary heart disease (CHD), AF and valve disease such as aortic stenosis and mitral stenosis. 5 - 7 , 11 , 12 Although there are few reports, the increased CA-125 levels is also documented in AMI. 7 - 9 …”

Section: Discussionmentioning

confidence: 99%

Role of plasma levels of CA-125 in predicting outcome of primary PCI after acute myocardial infarction in male patients

Separham

Abbasnezhad

Shahnazarli

et al. 2018

J Cardiovasc Thorac Res

View full text Add to dashboard Cite

Introduction: Cancer antigen 125 (CA-125) is a tumor marker of ovarian cancer, which has shown to be increased in different cardiovascular diseases. Although the prognostic role of CA-125 in heart failure and coronary heart disease is well-established, there is little known about its role in acute myocardial infarction (AMI). In this study we aimed to evaluate the serum levels of CA-125 in patients with AMI and its prognostic role in evaluating the in-hospital outcome of AMI. Methods: We evaluated 120 male patients with AMI and 120 male normal subjects. CA-125 levels were measured upon the patient’s admission to hospital. The in-hospital major adverse cardiac events (MACE) and its predictors were also recorded for AMI patients. Results: CA-125 levels were significantly higher in AMI patients compared to normal subjects (7.99±6.83 vs. 5.70±4.62, P = 0.003). We found significant positive correlations between CA-125 levels with creatine kinase-MB (CKMB) (r=0.621, P < 0.001) and CTnI (r=0.491, P < 0.001). The in-hospital MACE was observed in 19 cases (15.8%). Patients with MACE had significantly higher value of CA-125, CKMB and CTnI and lower LVEF compared to patients without MACE. CKMB (OR=0.967, 95% CI [0.943-0.991], P = 0.007) and CA-125 levels (OR=0.821, 95% CI [0.688-0.979], P = 0.02) were independent predictors of MACE. Conclusion: Serum CA-125 levels are significantly higher in male patients with AMI compared to normal subjects and have a significant role in predicting in-hospital MACE after AMI. In patients with higher CA-125 more aggressive treatment and close observation should be performed in order to reduce the possible adverse outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Role of plasma levels of CA-125 in predicting outcome of primary PCI after acute myocardial infarction in male patients

Separham

Abbasnezhad

Shahnazarli

et al. 2018

J Cardiovasc Thorac Res

View full text Add to dashboard Cite

show abstract

“…For ovarian cancer detection, the usual CA-125 cut-off level is >35 U/mL. 20 In contrast, Yucel et al 18 reported that the optimal cut-off level for CA-125 for predicting AF development was ≥68.49 U/mL in patients with systolic HF. Recently, Kaya et al 21 reported a retrospective cohort study where high CA-125 levels (≥91 U/mL) were predictors of the presence of permanent AF in patients with systolic HF.…”

Section: Discussionmentioning

confidence: 99%

“…Recently, several studies have reported the relationships between CA-125 and HF with reduced ejection fraction, HF with preserved ejection fraction 16 and ischaemic heart disease. 17 Yucel et al 18 reported that CA-125 levels are associated with the development of new-onset AF in patients hospitalised for systolic HF. However, no studies regarding the relationship between CA-125 and paroxysmal or persistent AF have been reported in healthy postmenopausal women.…”

Section: Introductionmentioning

confidence: 99%

Cancer antigen-125 plasma level as a biomarker of new-onset atrial fibrillation in postmenopausal women

Sekiguchi

Shimamoto

Takano

et al. 2017

Heart

View full text Add to dashboard Cite

ObjectivePlasma cancer antigen (CA)-125 is a tumour marker recently shown to be associated with systolic heart failure and new-onset atrial fibrillation (AF) after myocardial infarction. However, no reports have described the relationship between CA-125 and new-onset AF in healthy postmenopausal women. The aim of the present study was to evaluate the relationship between CA-125 and new-onset AF in postmenopausal women.MethodsBetween 2005 and 2015, 2086 women, including 1012 postmenopausal women, visited our hospital for annual health check-ups. We excluded patients with systolic dysfunction, chronic inflammatory disease, chronic obstructive pulmonary disease, histories of AF or neoplastic diseases. A total of 746 postmenopausal women underwent thorough physical examinations, including those for biomarkers such as brain natriuretic peptide, high-sensitivity C-reactive protein (hs-CRP) and CA-125.ResultsDuring the 10-year observation period, AF was documented in 31 participants (4.2%). The mean age of participants developing AF (75±6 years) was higher than that of those without AF (68±8 years). Participants developing AF showed significantly higher CA-125 (11.4±6.3 U/mL) and hs-CRP (0.10±0.11 mg/dL) levels than did those without AF (7.7±3.2 U/mL, p<0.01; 0.07±0.08 mg/dL, p<0.05). Cox regression analyses revealed ageing (HR 1.3; 95% CI 1.08 to 1.57; p<0.01) and plasma CA-125 levels (HR 1.29; 95% CI 1.10 to 1.51; p=0.02) as independent predictors of AF.ConclusionsHigh CA-125 levels might be associated with new-onset AF in healthy postmenopausal women.

show abstract

“…It is not surprising, therefore, to find that AF, in the current study, is an independent predictor for prolonged hospitalization in patients with HF. 14,17,19,43,44 In addition to high CA-125 levels and the presence of AF, lower sodium levels and higher creatinine levels are associated with prolonged LOS. This result, consistent with previous studies, is not surprising.…”

Section: Discussionmentioning

confidence: 99%

“…11 However, in the last decade, a correlation between serum CA-125 levels and cardiopulmonary diseases such as left-and rightsided HF, coronary artery disease, atrial fibrillation (AF), and chronic obstructive pulmonary disease (COPD), has been revealed. [12][13][14][15][16][17][18][19] Although serum CA-125 levels are significantly increased in HF and this increase correlates with the severity of the disease, the relationship between CA-125 and length of stay (LOS) in patients with HF has not yet been evaluated. This study is the first that attempts to evaluate the relationship between the duration of hospitalization and CA-125 levels in patients with HF.…”

mentioning

confidence: 99%

Cancer Antigen 125 is Associated with Length of Stay in Patients with Acute Heart Failure

Kaya¹,

Kurt²,

Beton³

et al. 2017

Texas Heart Institute Journal

View full text Add to dashboard Cite

Length of stay is the primary driver of heart-failure hospitalization costs. Because cancer antigen 125 has been associated with poor morbidity and mortality rates in heart failure, we investigated the relationship between admission cancer antigen 125 levels and lengths of stay in heart-failure patients. A total of 267 consecutive patients (184 men, 83 women) with acute decompensated heart failure were evaluated prospectively. The median length of stay was 4 days, and the patients were classified into 2 groups: those with lengths of stay ≤4 days and those with lengths of stay >4 days. Patients with longer lengths of stay had a significantly higher cancer antigen 125 level of 114 U/mL (range, 9–298 U/mL) than did those with a shorter length of stay (19 U/mL; range; 3–68) (P <0.001). The optimal cutoff level of cancer antigen 125 in the prediction of length of stay was >48 U/mL, with a specificity of 95.8% and a sensitivity of 96% (area under the curve, 0.979; 95% confidence interval [CI], 0.953–0.992). In the multivariate logistic regression model, cancer antigen 125 >48 U/mL on admission (odds ratio=4.562; 95% CI, 1.826–11.398; P=0.001), sodium level (P<0.001), creatinine level (P=0.009), and atrial fibrillation (P=0.015) were also associated with a longer length of stay after adjustment for variables found to be statistically significant in univariate analysis and correlated with cancer antigen 125 level. In addition, it appears that in a cohort of patients with acute decompensated heart failure, cancer antigen 125 is independently associated with prolonged length of stay.

show abstract

Cancer antigen 125 levels and increased risk of new-onset atrial fibrillation

Abstract: CA-125 level is associated with the development of AF in patients with hospitalized systolic HF.

Cited by 18 publications

References 26 publications

Role of plasma levels of CA-125 in predicting outcome of primary PCI after acute myocardial infarction in male patients

Role of plasma levels of CA-125 in predicting outcome of primary PCI after acute myocardial infarction in male patients

Cancer antigen-125 plasma level as a biomarker of new-onset atrial fibrillation in postmenopausal women

Cancer Antigen 125 is Associated with Length of Stay in Patients with Acute Heart Failure

Contact Info

Product

Resources

About